Presentation is loading. Please wait.

Presentation is loading. Please wait.

ADAb: anti-drug antibody.

Published byVítor Azevedo Modified over 5 years ago

Similar presentations

Presentation on theme: "ADAb: anti-drug antibody."— Presentation transcript:

1 ADAb: anti-drug antibody.
Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the British Society for Rheumatology.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact Rheumatology (Oxford), kez030, The content of this slide may be subject to copyright: please see the slide notes for details.

2 ADAbs: anti-drug ... ADAbs: anti-drug antibodies; AEs: adverse events; NA: not available; TF: treatment failure; +: strong association with ADAbs; +/−: possible association with ADAbs; −: no association with ADAbs. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the British Society for Rheumatology.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact Rheumatology (Oxford), kez030, The content of this slide may be subject to copyright: please see the slide notes for details.

3 Fig. 3 Random effects meta-analysis of concomitant MTX and the risk of ADAb development during adalimumab ... ADAbs: anti-drug antibodies; RR: risk ratio. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the British Society for Rheumatology.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact Rheumatology (Oxford), kez030, The content of this slide may be subject to copyright: please see the slide notes for details.

4 Fig. 4 Course of action for treatment failure or hypersensitivity during JIA treatment with biologic ... Treatment failure (primary or secondary) or hypersensitivity-associated events: assess serum drug trough concentration. (i) Sufficient drug concentration: switch to a biologic agent of a different class. (ii) Insufficient drug concentration: measure ADAbs. (a) ADAb-negative: (1) assess and (re-)adjust dosage to patient’s weight; (2) assess and optimize therapeutic compliance; (3) optimal compliance and maximum dosage: switch to a biologic agent of a different class. (b) ADAb-positive: neutralize ADAbs: (1) immunosuppressive therapy, (2) dose escalation, (3) switch to another biologic agent – identical or different class. ADAb: anti-drug antibody; ?: research question for future research. Unless provided in the caption above, the following copyright applies to the content of this slide: © The Author(s) Published by Oxford University Press on behalf of the British Society for Rheumatology.This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact Rheumatology (Oxford), kez030, The content of this slide may be subject to copyright: please see the slide notes for details.

Download ppt "ADAb: anti-drug antibody."

Similar presentations

Table 1 Patient characteristics of attendees of the influenza vaccination, irrespective of AF status From: Yield of screening for atrial fibrillation in.

Table 1 Patient characteristics of attendees of the influenza vaccination, irrespective of AF status From: Yield of screening for atrial fibrillation in.
Fig 1 The CONSORT participant flow diagram for primary endpoints.

Fig 1 The CONSORT participant flow diagram for primary endpoints.
From: Learning by Working in Big Cities

From: Learning by Working in Big Cities
Fig. 1 Nodes in a conceptual knowledge graph

Fig. 1 Nodes in a conceptual knowledge graph
Figure 1: Pneumomediastinum and subcutaneous emphysema as indicated by the arrows. From: Pneumomediastinum and subcutaneous emphysema after successful.

Figure 1: Pneumomediastinum and subcutaneous emphysema as indicated by the arrows. From: Pneumomediastinum and subcutaneous emphysema after successful.
From: Epidemiology of Inappropriate Empiric Antibiotic Therapy for Bacteremia Based on Discordant In vitro Susceptibilities: Risk factors and Taxon-level.

From: Epidemiology of Inappropriate Empiric Antibiotic Therapy for Bacteremia Based on Discordant In vitro Susceptibilities: Risk factors and Taxon-level.
From: Detection of Bacteriuria by Canine Olfaction

From: Detection of Bacteriuria by Canine Olfaction
Figure 1. The flow chart illustrates the construction process of anti-CRISPRdb, and the information that users can obtain from anti-CRISPRdb. From: Anti-CRISPRdb:

Figure 1. The flow chart illustrates the construction process of anti-CRISPRdb, and the information that users can obtain from anti-CRISPRdb. From: Anti-CRISPRdb:
Figure 1: Necrobiosis lipoidica: Yellow-brown skin lesions with indurated borders located on both lower legs. Figure 1: Necrobiosis lipoidica: Yellow-brown.

Figure 1: Necrobiosis lipoidica: Yellow-brown skin lesions with indurated borders located on both lower legs. Figure 1: Necrobiosis lipoidica: Yellow-brown.
Figure 1. Circular taxonomy tree based on the species that were sequenced in our study. Unless provided in the caption above, the following copyright applies.

Figure 1. Circular taxonomy tree based on the species that were sequenced in our study. Unless provided in the caption above, the following copyright applies.
FIGURE 1 Kidney biopsies of Patients 1 and 2

FIGURE 1 Kidney biopsies of Patients 1 and 2
Figure 1 Hazard ratios as a function of annual mean PM2

Figure 1 Hazard ratios as a function of annual mean PM2
Figure 1: Axial T2 W images of penis showed a well-defined septated area of 2 cm in the posterior aspect of ... Figure 1: Axial T2 W images.

Figure 1: Axial T2 W images of penis showed a well-defined septated area of 2 cm in the posterior aspect of ... Figure 1: Axial T2 W images.
FIGURE 1 Histological diagnoses divided into 8-year time frames (n = 1208). Unless provided in the caption above, the following copyright applies to the.

FIGURE 1 Histological diagnoses divided into 8-year time frames (n = 1208). Unless provided in the caption above, the following copyright applies to the.
FIGURE 1 The effect of daprodustat on hemoglobin (Hgb) levels

FIGURE 1 The effect of daprodustat on hemoglobin (Hgb) levels
FIGURE 2 Responses to the question: regarding vasoactive drugs, does your centre use the following frequently, rarely ... FIGURE 2 Responses to the question:

FIGURE 2 Responses to the question: regarding vasoactive drugs, does your centre use the following frequently, rarely ... FIGURE 2 Responses to the question:
FIGURE 1 Maternal (A) urinary aldosterone; (B) plasma active renin; (C) urinary AGT concentrations; and (D) plasma AGT ... FIGURE 1 Maternal (A) urinary.

FIGURE 1 Maternal (A) urinary aldosterone; (B) plasma active renin; (C) urinary AGT concentrations; and (D) plasma AGT ... FIGURE 1 Maternal (A) urinary.
Fig. 1 Bone scintigraphy of the right tibia of the patient at disease onset (A), after 10 years of calcitonin ... Fig. 1 Bone scintigraphy of the right.

Fig. 1 Bone scintigraphy of the right tibia of the patient at disease onset (A), after 10 years of calcitonin ... Fig. 1 Bone scintigraphy of the right.
FIGURE 1 Flow chart of patient enrollment and exclusion

FIGURE 1 Flow chart of patient enrollment and exclusion
Figure 1. Ratios of observed to expected numbers of exon boundaries aligning to boundaries of domain and disorder ... Figure 1. Ratios of observed to expected.

Figure 1. Ratios of observed to expected numbers of exon boundaries aligning to boundaries of domain and disorder ... Figure 1. Ratios of observed to expected.

Similar presentations

Ads by Google